1. Darren Cunningham CEO dcunningham@inflectionbio.com
Presentation by
Darren Cunningham
CEO

2. Overview 1 in 3 will get cancer – many will not survive ***
Our mission
develop groundbreaking new treatments for those suffering with cancer

3. Business Model Value Inflection: 10-15 YEAR DEVELOPMENT LEAD
DISC
TARGET
HITS
LEAD
PRE-CLIN
IND
PHASE 1
PHASE 2
PHASE 3
APP
LAUNCH
LEAD
PRE-CLINICAL
IND PACKAGE
EARLY
CLINICAL
LICENSE IN
PARTNER/ EXIT/IPO
Value Inflection:
4 – 5 YEAR DEVELOPMENT

4. Phase I Value Creation Potential
Phase I Oncology Exits
$100m - >$300m

5. Collaboration with CNIO - June 2013
Spanish National Cancer Research Centre

6. Secure Partner after Phase I
Pipeline – Targeted Therapeutics
TARGET
RESEARCH
PRE-CLIN
IND
PHASE I
NSCLC
Secure Partner after Phase I
IBL-300s (PIM/PI3K/mTOR)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
IBL-202 (PIM/PI3K)
MULTIPLE MYELOMA
B-CELL LYMPHOMAS
IBL-100s (Pan-PIM)
HAEM MALIGNANCIES
Secure Partner at IND
Comprising first-in-class agents protected by composition of matter patents

7. PIM Kinase a driver of resistance in AKT/PI3K
PIM expression dramatically elevated by PI3K/AKT pathway inhibition
PIM mediates feedback loop driving acquired resistance to a number of treatment modalities.
Underpins rationale for co-targeting PI3K and PIM;
huge clinical opportunity

8. Lung cancer leading cause of cancer death (1.6m ww)
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
Lung cancer leading cause of cancer death (1.6m ww)
- NSCLC ~80% = $10bn market by 2020
De novo PI3k activation
Mutant K-Ras
EGFR TKI Resistant
Squamous cc – PIK3CA/ PTEN mutations ~30%
PIM and PI3K inhibitors act synergistically in vitro and in vivo
PIM mediates PI3K/AKT resistance
NSCLC - K-Ras mutated in 15-30%
Downstream activation include PI3K/AKT/mTOR
PIM inhibition shuts down growth in mutant K-Ras NSCLC cell lines
NSCLC - EGFR mutations in ~10% de novo
Cancer recurs (~12mo) with ~10% due to PI3K activation
PIM elevated in EGFR TKI resistant lines
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s

9. Research Collaboration Network
Network spanning US, EU, Australia
NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL, MCL, CLL, neuroblastoma, breast cancer, mechanistic

10. ONCOLOGY ADVISORY PANEL
Leadership
MANAGEMENT
ONCOLOGY ADVISORY PANEL
Darren Cunningham CEO
15 year record in licensing, M&A, IP, fundraising, IR
Amarin, Elan, PWC
B. Comm, M. Acc, FCA
Dr. Michael O’Neill
Director R&D
22 year drug discovery and development
Eli Lilly, Almirall, Merck
BA Psychology, PhD
Dr. Martin Page
30+ years experience in oncology R&D
Previous VP, Global Head of Oncology Res. J&J
Roles with OSI Pharma, Oxford Glycosciences, and Glaxo-Wellcome
Prof. Josep Tabernero
Director, Vall d’Hebron Institute of Oncology
Led clinical development of PI3K pathway inhibitors
ESMO Executive Board
Prof. Funda Meric-Bernstam
Professor of Surgical Oncology; and
Chair Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center

11. Corporate profile Incorporated 2012
Headquartered in Dublin, with base in London
2 full time employees
Internship program, 3 in 2015
PhD in TCD via Innovation Partnership
6 board members; panel of international scientific advisors
6 CROs (UK, France, China, India)
>10 research collaborations (US, Ireland, UK, Germany, Sweden, Australia)
~€2.2m raised to date (EI, VC and privates)

12. Thank you
Darren Cunningham